Understanding how BARD1 and PLK1 interactions affect pancreatic cancer treatment
Elucidating the relevance of BARD1-PLK1 interaction in PDAC and response to therapy
This study is looking at how a protein called BARD1 affects pancreatic cancer and its response to treatments, especially for patients with certain genetic changes, to find better ways to help those who have fewer treatment options.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10888373 on NIH RePORTER |
What this research studies
This research investigates the role of the BARD1 protein in pancreatic ductal adenocarcinoma (PDAC) and how it interacts with PLK1 to influence treatment responses. By studying the effects of BARD1 on cancer cell behavior, particularly in tumors with specific genetic mutations like BRCA1/2, the research aims to identify new therapeutic targets that could enhance the effectiveness of existing treatments. Patients with HRR deficient tumors may benefit from this approach, as the study seeks to improve treatment outcomes for those who currently have limited options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, especially those with BRCA1/2 mutations or homologous recombination repair deficiencies.
Not a fit: Patients with pancreatic cancer who do not have BRCA1/2 mutations or other related genetic deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for pancreatic cancer patients, particularly those with specific genetic profiles.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in other cancers, suggesting potential for success in this novel approach for pancreatic cancer.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Jain, Aditi — Thomas Jefferson University
- Study coordinator: Jain, Aditi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.